-       Report 
- April 2025
-  105 Pages 
- Global 
   From       €5322EUR$5,950USD£4,681GBP 
            -       Report 
- October 2025
-  181 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Report 
- October 2025
-  197 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Report 
- August 2025
-  188 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
          -       Report 
- October 2025
-  402 Pages 
- Global 
   From       €5233EUR$5,850USD£4,603GBP 
           -       Report 
- September 2025
-  250 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- September 2025
-  250 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- September 2025
-  250 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- April 2025
-  200 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- May 2025
-  87 Pages 
- Global 
   From       €3500EUR$4,192USD£3,186GBP 
          -       Report 
- April 2024
-  88 Pages 
- Global 
   From       €3500EUR$4,192USD£3,186GBP 
          -       Report 
- January 2024
-  77 Pages 
- Global 
   From       €3500EUR$4,192USD£3,186GBP 
          -       Report 
- October 2025
-  50 Pages 
- Global 
   From       €2370EUR$2,650USD£2,085GBP 
          -       Report 
- October 2024
- Global 
   From       €3131EUR$3,500USD£2,754GBP 
       
      Tobramycin is an aminoglycoside antibiotic used to treat a variety of bacterial infections. It is commonly used to treat respiratory tract infections, urinary tract infections, and skin and soft tissue infections. Tobramycin is also used to treat certain types of meningitis and sepsis. It is usually administered intravenously or intramuscularly, and is available in both generic and branded forms.
Tobramycin is a widely used antibiotic, and is often used in combination with other antibiotics to    treat more serious infections. It is generally well tolerated, with few side effects. However, it can cause nephrotoxicity and ototoxicity, and should be used with caution in patients with renal impairment.
The tobramycin market is highly competitive, with a number of companies offering branded and generic versions of the drug. Some of the major players in the market include Pfizer, Merck, Novartis, Sanofi, and Mylan. Show Less   Read more